Subscribe to Search results

A note from M Draper to Thomas Dutton noted that Dr Owen had asked to have a copy of the MRC report from which the Haemophilia Society were quoting and which had also mentioned Dr Rosemary Biggs.

Published on:

RTD (75) 26 set out regional transfusion directors' estimates of the number of donations to be used for the production of fresh plasma from AHG concentrate each quarter from 1975 to mid 1977.

Published on:

A memo from Thomas Dutton noted that a recent meeting of the Expert Group on the Treatment of Haemophilia advised that NHS Factor 8 production may have provided no more than about one third of the likely requirement for Factor 8 in a few years time.

Published on:

A note on anti-haemophilic globulin concentrate outlined that the target figure to which they were currently working was no longer sufficient to meet the probable treatment needs of people with haemophilia in a few years time, having been overtaken by the unexpected rapid introduction of home therapy.

Published on:

A letter from Gerry Grimstone to Thomas Dutton outlined Dr Owen's stance that the National Blood Transfusion Service needed to be reformed.

Published on:

In a National Blood Transfusion Service Central Committee meeting, the chairman proposed a review of the clinical use of blood and blood products, including an examination of the overall use of the blood and blood fractions.

Published on:

A document by T Dutton outlined problems facing the National Blood Transfusion Service, particularly with regard to the provision of blood components.

Published on:

The draft proof of "Evidence of Dr Lane for HIV Litigation" noted that Dr Ethel Bidwell's note on the production of Factor 8 concentrate (including arithmetic on the basis of yields) in January 1976 was far closer to what Dr Lane would consider realistic.

Published on:

The minutes of a haemophilia centre directors' meeting noted that there was a hold up in the expansion of fractionation in the UK.

Published on:

The Working Group on Trends in the Demand for Blood Products held its first meeting.

Published on:

The Working Group on Trends in the Demand for Blood Products noted in its July meeting that the size of the population with haemophilia could rise significantly. They also said: "It was apparent that clinicians were coming to recognise the supply problems; eg, they were moderating their demands for Factor VIII for prophylactic treatment."

Published on:

The estimates which had been reported by the Working Group on Trends in the Demand for Blood Products in late 1977 were largely thought to be reliable estimates for future need by the Standing Medical Advisory Committee in 1978.

Published on:

The Standing Medical Advisory Committee was constituted by the National Health Service Act 1946 and Dr Waiter noted that the Committee expected an increasing requirement for Factor 8 for orthopaedic surgery and David Smart recorded the modified figures.

Published on:

Dr Lane considered in 1979 that a redeveloped BPL could be commissioned to increase production capacity to 90 million international units between 1985 and 1990, as an intermediate stage, and then to scale up production to 120 million units for the years that followed.

Published on:

The approval given by the Treasury in November 1982 for the reconstructed BPL was for a plant capable of fractionating 400,000 kilograms per annum.

Published on:

If the PFC processed plasma to produce Factor 8 for England, then less would be needed to be spent on BPL, since BPL would then process smaller quantities of plasma, and since smaller quantities required less manufacturing space and equipment, it would cost less to build.

Published on:

A plasma supply target of 435,000 kilograms was broadly maintained, and although estimates thereafter continued to increase, there was a growing consensus that demand for Factor 8 would increase to the region of 100 million international units. The increases in estimated needs were by this time gradual compared to those that came before.

Published on:

Peter Wormald, Under-Secretary in the DHSS, understood that the reasons for the policy of self-sufficiency was "that imported products were very expensive and in general were considered to carry much higher risk of cross-infections, particularly hepatitis".

Published on:

Peter Wormald noted that "although no decision had been yet on the redevelopment of BPL, there was a need to determine its future capacity; which in turn raised the issue of what part Liberton would play in meeting capacity."

Published on:

Peter Wormald noted "There appear to have been some follow-up discussions, but I was not copied into the papers and I do not know what action, if any, resulted. It is possible that the discussions took a back seat in September when the Medicines Inspectors' report on BPL was presented."

Published on: